Logo image of ACET

ADICET BIO INC (ACET) Stock Fundamental Analysis

NASDAQ:ACET - US0070021086 - Common Stock

0.7367 USD
+0.03 (+3.61%)
Last: 8/26/2025, 8:13:45 PM
0.7499 USD
+0.01 (+1.79%)
Pre-Market: 8/27/2025, 8:00:00 AM
Fundamental Rating

3

Overall ACET gets a fundamental rating of 3 out of 10. We evaluated ACET against 547 industry peers in the Biotechnology industry. While ACET has a great health rating, there are worries on its profitability. ACET does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ACET has reported negative net income.
ACET had a negative operating cash flow in the past year.
In the past 5 years ACET always reported negative net income.
In the past 5 years ACET always reported negative operating cash flow.
ACET Yearly Net Income VS EBIT VS OCF VS FCFACET Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M

1.2 Ratios

ACET has a Return On Assets (-61.23%) which is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -72.54%, ACET is in line with its industry, outperforming 55.21% of the companies in the same industry.
Industry RankSector Rank
ROA -61.23%
ROE -72.54%
ROIC N/A
ROA(3y)-47.68%
ROA(5y)-37.04%
ROE(3y)-56.8%
ROE(5y)-44.85%
ROIC(3y)N/A
ROIC(5y)N/A
ACET Yearly ROA, ROE, ROICACET Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for ACET so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACET Yearly Profit, Operating, Gross MarginsACET Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

More info and screens

7

2. Health

2.1 Basic Checks

Compared to 1 year ago, ACET has more shares outstanding
ACET has more shares outstanding than it did 5 years ago.
ACET has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ACET Yearly Shares OutstandingACET Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M
ACET Yearly Total Debt VS Total AssetsACET Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -3.94, we must say that ACET is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -3.94, ACET perfoms like the industry average, outperforming 44.24% of the companies in the same industry.
There is no outstanding debt for ACET. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.94
ROIC/WACCN/A
WACCN/A
ACET Yearly LT Debt VS Equity VS FCFACET Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 9.34 indicates that ACET has no problem at all paying its short term obligations.
The Current ratio of ACET (9.34) is better than 79.71% of its industry peers.
A Quick Ratio of 9.34 indicates that ACET has no problem at all paying its short term obligations.
With a decent Quick ratio value of 9.34, ACET is doing good in the industry, outperforming 79.89% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.34
Quick Ratio 9.34
ACET Yearly Current Assets VS Current LiabilitesACET Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.22% over the past year.
EPS 1Y (TTM)48.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.03%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.72% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y8.78%
EPS Next 2Y10.47%
EPS Next 3Y8.54%
EPS Next 5Y14.72%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACET Yearly Revenue VS EstimatesACET Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2027 2028 2029 2030 2031 2032 100M 200M 300M
ACET Yearly EPS VS EstimatesACET Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

ACET reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ACET. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACET Price Earnings VS Forward Price EarningsACET Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACET Per share dataACET EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.47%
EPS Next 3Y8.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACET!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ADICET BIO INC

NASDAQ:ACET (8/26/2025, 8:13:45 PM)

Premarket: 0.7499 +0.01 (+1.79%)

0.7367

+0.03 (+3.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-04 2025-11-04/amc
Inst Owners53.58%
Inst Owner Change-3.47%
Ins Owners1.5%
Ins Owner Change2.04%
Market Cap61.33M
Analysts83.08
Price Target6.12 (730.73%)
Short Float %5.85%
Short Ratio8.6
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.87%
Min EPS beat(2)8.37%
Max EPS beat(2)13.38%
EPS beat(4)4
Avg EPS beat(4)8.73%
Min EPS beat(4)2.1%
Max EPS beat(4)13.38%
EPS beat(8)6
Avg EPS beat(8)-1.64%
EPS beat(12)7
Avg EPS beat(12)-15.67%
EPS beat(16)10
Avg EPS beat(16)-0.28%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-6.25%
PT rev (3m)-6.25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.76%
EPS NY rev (1m)-2.82%
EPS NY rev (3m)-1.67%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.38
P/tB 0.38
EV/EBITDA N/A
EPS(TTM)-1.31
EYN/A
EPS(NY)-1.04
Fwd EYN/A
FCF(TTM)-1.17
FCFYN/A
OCF(TTM)-1.14
OCFYN/A
SpS0
BVpS1.94
TBVpS1.94
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -61.23%
ROE -72.54%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.68%
ROA(5y)-37.04%
ROE(3y)-56.8%
ROE(5y)-44.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 36.47%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.34
Quick Ratio 9.34
Altman-Z -3.94
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)246.96%
Cap/Depr(5y)333.75%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.22%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-3.03%
EPS Next Y8.78%
EPS Next 2Y10.47%
EPS Next 3Y8.54%
EPS Next 5Y14.72%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.6%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-32.24%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-9.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-29.88%
OCF growth 3YN/A
OCF growth 5YN/A